Microba Life Sciences Limited (ASX:MAP)

Australia flag Australia · Delayed Price · Currency is AUD
0.0820
0.00 (0.00%)
At close: Mar 6, 2026
-56.84%
Market Cap 49.93M
Revenue (ttm) 14.90M
Net Income (ttm) -19.75M
Shares Out 608.96M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 292,437
Average Volume 217,161
Open 0.0820
Previous Close 0.0820
Day's Range 0.0760 - 0.0820
52-Week Range 0.0690 - 0.2300
Beta 2.37
RSI 45.65
Earnings Date Apr 20, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution... [Read more]

Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol MAP
Full Company Profile

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.

Financial Statements

News

There is no news available yet.